ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a biopharmaceutical company headquartered in San Diego, California, specializing in the development of innovative treatments for severe allergic reactions. Founded in 2015, the company focuses on creating needle-free solutions to improve patient outcomes and accessibility.
The company’s flagship product, neffy, is a needle-free, low-dose intranasal epinephrine nasal spray designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. This novel delivery method aims to provide a convenient and effective alternative to traditional epinephrine auto-injectors, enhancing patient compliance and ease of use.
In August 2024, ARS Pharmaceuticals received FDA approval for neffy, marking a significant milestone in the company’s mission to offer accessible emergency treatments for allergic reactions. Following this approval, in November 2024, ARS Pharmaceuticals entered into a strategic licensing agreement with ALK-Abelló A/S, granting ALK exclusive global rights to commercialize neffy outside the United States, Australia, New Zealand, Japan, and China. This partnership is expected to expand the global reach of neffy, making it available to a broader patient population.
ARS Pharmaceuticals’ growth strategy centers on innovation in drug delivery systems, strategic partnerships to enhance market penetration, and a commitment to addressing unmet medical needs in allergy treatment. By focusing on patient-friendly solutions and leveraging collaborations with established pharmaceutical companies, ARS Pharmaceuticals aims to solidify its position in the biopharmaceutical industry and improve the standard of care for patients with severe allergies.
Click The Image For Current Live Chart